布鲁顿酪氨酸激酶抑制剂泽布替尼治疗免疫性血小板减少症的疗效与安全性
这项单臂II期研究评估泽布替尼治疗糖皮质激素耐药或复发免疫性血小板减少症(ITP)的疗效与安全性,20例患者接受泽布替尼80 mg每日一次共6周。11例(55%,95%CI:31.5%-76.9%)获得总体反应,2例(10%)获得完全反应,6个月随访时7例(35.0%,95%CI:15.4%-59.2%)维持持续反应。未发生4级或更严重不良事件或治疗相关死亡。
要点
- 糖皮质激素耐药或复发ITP患者中,泽布替尼总体反应率为55%(95%CI:31.5%-76.9%)。
- 完全反应率为10%,6个月持续反应率为35.0%(95%CI:15.4%-59.2%)。
- 未发生4级或更严重不良事件或治疗相关死亡,最常见不良事件为上呼吸道感染(25%)。
核心结论
- 泽布替尼在糖皮质激素耐药或复发ITP中显示出令人鼓舞的反应率和耐受性,支持其治疗ITP的治疗潜力。
研究设计与样本
- 单臂II期研究,纳入20例糖皮质激素耐药或复发ITP患者,所有患者接受泽布替尼80 mg每日一次共6周,随后20周安全性随访期。
- 主要终点为总体反应(OR),定义为4周时至少连续两次血小板计数至少30×10^9/L、较基线计数至少增加2倍、无出血且无需挽救治疗。
- 试验注册于ClinicalTrials.gov,注册号NCT05279872,入组时间为2022年1月1日至2022年10月30日。
主要发现
- 入组时中位血小板计数为19(10-25)×10^9/L,参与者既往接受过中位4(3-6)种不同ITP治疗。
- 11例(55%,95%CI:31.5%-76.9%)患者获得总体反应,2例(10%)获得完全反应。
- 6个月随访时,7例(35.0%,95%CI:15.4%-59.2%)患者获得持续反应。
- 未发生4级或更严重不良事件或治疗相关死亡,最常见不良事件为上呼吸道感染(25%的患者)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is characterized by impaired platelet production and increased platelet destruction. Zanubrutinib is a highly selective next-generation Bruton tyrosine kinase (BTK) inhibitor that may reduce autoantibody production and reduce macrophage Fcγ receptor-mediated platelet destruction. In this single-arm, phase II study, we aimed to assess the efficacy and safety of zanubrutinib in corticosteroid-resistant or relapsed ITP. All patients received 80 mg zanubrutinib once daily for 6 weeks followed by a 20-week safety follow-up period. The primary endpoint was overall response (OR), defined as at least two consecutive platelet counts of at least 30 × 109/L, at least a 2-fold increase in the baseline count, the absence of bleeding, and no need for rescue therapy at 4 weeks. The trial was registered with ClinicalTrials.gov, number NCT05279872. Between January 1, 2022 and October 30, 2022, 20 patients were enrolled. The median platelet count was 19 (10-25) × 109/L at the time of enrollment. Participants had received a median of 4 (3-6) different therapies for ITP. Eleven (55%, 95% CI: 31.5%-76.9%) patients achieved an OR to the intervention. Two (10%) patients achieved a complete response. At the 6-month follow-up, a sustained response was achieved in seven (35.0%, 95% CI: 15.4%-59.2%) patients. There were no grade 4 or worse adverse events or treatment-related deaths. The most common adverse events were upper respiratory tract infection (in 25% of the patients). Zanubrutinib showed an encouraging response rate and tolerability, supporting its therapeutic potential for the treatment of ITP. Trial Registration: ClinicalTrials.gov identifier: NCT05279872.
引用
- Huang QS, Fu HX, Wang CC, et al. Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia. Am J Hematol. 2025. PMID: 40391880. doi:10.1002/ajh.27718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。